|
|
Emergent Technologies,
Inc.
Thomas A. Harlan, Chairman, President, and Chief Executive Officer
800 Research Parkway, Suite 340
Oklahoma City, OK 73104
Phone: 405/271-3838
Fax: 405/271-3848
www.emergenttechnologies.com
ETI is a regionally-based venture capital and management services
firm that specializes in forming, funding, commercializing, and
managing companies for the purpose of converting institutional and
university-based technology into high return ventures. Its unique
process matches breakthrough technology with commercialization partners
who can validate the market potential and expeditiously bring the
technology to market. Investors can have confidence that risks will
be reduced and the time to liquidity accelerated because ETI's process
avoids unproven technologies, large front-end investments, and dependency
on the IPO market.
ETI created its first investment fund, Emergent-OU, Ltd., in 1999
to launch three technologies emanating from the University of Oklahoma
Health Sciences Center in Oklahoma City, OK. Its second fund, Emergent
Technologies Oklahoma, L.P. was created in 2000 to make further
investments in the first three companies and provided seed capital
for the fourth and fifth companies.
Pure Protein has developed a unique method to produce soluble
HLA protein from human cell lines. The company is focused on the
discovery of new targets to prevent and treat infectious disease
and cancer. Pure Protein's core technology platform allows the production
of large quantities of immune surveillance proteins and provides
unique insight to the inner workings of diseased cells. It has created
two subsidiaries, Pure Transplant Solutions, L.L.C. and Pure Vaccine
Solutions, L.L.C. The Pure Protein platform enables a distinct toolset
for evaluating and improving vaccines as well as reducing unwanted
allergic reactions from bio therapeutics.www.pureproteinllc.com
Hyalose, L.L.C. has developed unique capabilities for the
recombinant production of hyaluronic acid both in bulk production
using fermentation and in enzymatic synthesis where a very high
level of control is possible in determining the exact molecule that
is synthesized. Controlled enzymatic synthesis also enables the
placement of other glycosaminoglycan sugars and unnatural sugars
at precisely defined positions in the sugar chain creating new novel
sugar compounds. The company has licensed several genes from different
species of bacteria that synthesize hyaluronic acid.www.hyalose.com
MedUnison – Formerly known as MedSynergy, MedUnison's
DocSynergy is an online, secure medical community for physicians
and other healthcare providers to dramatically improve the quality
of healthcare delivery, while significantly lowering the cost of
treatment. The DocSynergy solution harnesses the benefits of distance
medicine through unique technology to enable physicians to tap the
expertise and knowledge of colleagues regardless of location. The
DocSynergy solution is built for the rural physician, the urban
specialty group, and physicians working with captured patients,
such as those in correctional facilities. ../med
Heparinex, L.L.C. is a biopharmaceutical company focusing
on the novel recombinant synthesis of compounds for the growing
anticoagulation market and associated arenas. The core technology
platform was originally discovered and patented by a leading carbohydrate
chemist/ glycobiologist at the University of Oklahoma in 2002. Heparinex’s
core platforms employ (a) bacterial production techniques and (b)
in vitro defined polymer syntheses to provide uniquely controlled
non-animal sources of genetically customizable heparinoid compounds
for drug discovery, therapeutic formulations and medical device
applications. www.heparinex.com
Choncept is a biotech company focused on development of new
technology to produce chondroitin from fermentation of recombinant
bacteria to replace the current chondroitin source of beef and other
animal by-products. Chondroitin produced by the gene patented by
Choncept is unsulfated which can be sulfated to produce chondroitin
similar to that isolated from animal sources. The unsulfated chondroitin
may also be of interest as a biomaterial. Chondroitin produced recombinantly
may be significantly less expensive to produce than current methods
that rely on animal by-products. Modified chondroitin, dermatan
sulfate, has properties as an anti-coagulant, an important pharmaceutical
market. www.choncept.com
|
|